Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov;107 Suppl 1(0 1):45-52.
doi: 10.1111/j.1360-0443.2012.04038.x.

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

Affiliations
Randomized Controlled Trial

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

Karol Kaltenbach et al. Addiction. 2012 Nov.

Abstract

Aim: To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero.

Design and setting: Multi-site randomized clinical trial in which infants were observed for a minimum of 10 days following birth, and assessed for NAS symptoms by trained raters.

Participants: A total of 131 infants born to opioid dependent mothers, 129 of whom were available for NAS assessment.

Measurements: Generalized linear modeling was performed using maternal and infant characteristics to predict: peak NAS score prior to treatment, whether an infant required NAS treatment, length of NAS treatment and total dose of morphine required for treatment of NAS symptoms.

Findings: Of the sample, 53% (68 infants) required treatment for NAS. Lower maternal weight at delivery, later estimated gestational age (EGA), maternal use of selective serotonin re-uptake inhibitors (SSRIs), vaginal delivery and higher infant birthweight predicted higher peak NAS scores. Higher infant birthweight and greater maternal nicotine use at delivery predicted receipt of NAS treatment for infants. Maternal use of SSRIs, higher nicotine use and fewer days of study medication received also predicted total dose of medication required to treat NAS symptoms. No variables predicted length of treatment for NAS.

Conclusions: Maternal weight at delivery, estimated gestational age, infant birthweight, delivery type, maternal nicotine use and days of maternal study medication received and the use of psychotropic medications in pregnancy may play a role in the expression of neonatal abstinence syndrome severity in infants exposed to either methadone or buprenorphine.

Trial registration: ClinicalTrials.gov NCT00271219.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

This study was funded by the National Institute on Drug Abuse. No contractual constraints on publishing were imposed by the funding body.

The clinical trial was registered with ClinicalTrials.gov (Identifier: NCT00271219; Title: RCT Comparing Methadone and Buprenorphine in Pregnant Women)

H.J. discloses that she has received reimbursement for time and travel from Reckitt Benckiser.

References

    1. National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43. - PubMed
    1. Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126:170–5. - PubMed
    1. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: Effects and management. Obstet Gynecol Clin North Am. 1998;25:139–51. - PubMed
    1. Jarvis MA, Schnoll SH. Methadone treatment during pregnancy. J Psychoactive Drugs. 1994;26:155–61. - PubMed
    1. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson NM, Seidel HM, editors. Primary pediatric care. 2. St Louis MO: Mosby Year Book; 1992. pp. 1367–78.

Publication types

MeSH terms

Associated data